Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Pooled allogeneic fecal microbiotherapy

Phase 2Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Complication

NCT05762211

Clinical

Trials by Indication[1]

Complication1 trial

Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)

Recruiting·MMaaT Pharma·Phase 2·NCT05762211·387 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Pooled allogeneic fecal microbiotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pooled allogeneic fecal microbiotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pooled allogeneic fecal microbiotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — MaaT Pharma company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMaaT Pharma

Related News